pericytes ip  (AMS Biotechnology)

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: TEER (Ω/cm 2 ) of static (S) EP + A in vitro BBB model over 120 h on different substrata. Endothelial cells (E), Pericytes (P) and Astrocytes (A), Fibronectin (F), Gelatin (G) Fibronectin + Collagen (F + C), Fibronectin + Gelatin (F + G), n = 9 ± SD, *** = p < 0.001; statistical analysis was performed using two-way ANOVA Bonferroni post hoc tests.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques: In Vitro

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: TEER (Ω/cm 2 ) of dynamic (D) EP + A in vitro BBB model over 120 h on different substrata. Endothelial cells (E), Pericytes (P) and Astrocytes (A), Fibronectin (F), Gelatin (G) Fibronectin + Collagen (F + C), Fibronectin + Gelatin (F + G), n = 9 ± SD, * = p < 0.05, *** = p < 0.001; statistical analysis was performed using two-way ANOVA Bonferroni post hoc tests.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques: In Vitro

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: TEER (Ω/cm 2 ) of dynamic (D) mono- and tri-culture in vitro BBB models over 120 h on Fibronectin + Gelatin (F + G) substratum combination, Endothelial cells (E), Pericytes (P) and Astrocytes (A), n = 9 ± SD, *** = p < 0.001; statistical analysis was performed using two-way ANOVA Bonferroni post hoc tests.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques: In Vitro

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: TEER (Ω/cm 2 ) of two different dynamic (D) in vitro BBB models over 120 h with and without magnesium (Mg 2+ ). Fibronectin + Gelatin (F + G), Endothelial cells (E), Pericytes (P) and Astrocytes (A). n = 9 ± SD, *** = p < 0.001; statistical analysis was performed using two-way ANOVA Bonferroni post hoc tests.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques: In Vitro

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: TEER (Ω/cm 2 ) of dynamic (D) models: endothelial monolayer N/S, endothelial monolayer F + G Mg 2+ and EP + A F + G Mg 2+ . N/S = no substratum, E = endothelial cells, P = pericyte, A = astrocyte, F + G = fibronectin + gelatin and Mg = magnesium. n = 9 ± SD, *** = p < 0.001; statistical analysis was performed using two-way ANOVA Bonferroni post hoc tests.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques:

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: Image of Western blot membrane, detecting ZO1 TJ-protein (mw 195 kDA) in lysed cells from different in vitro BBB models. Endothelial cells (E), Pericytes (P), Astrocytes (A), Fibronectin + Gelatin (F + G), Fibronectin + Collagen (F + C), No substrata (NS) and Magnesium (Mg 2+ ), Dynamic mode.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques: Western Blot, Membrane, In Vitro

Journal: Pharmaceutics

Article Title: Non-Invasive, Targeted Nanoparticle-Mediated Drug Delivery across a Novel Human BBB Model

doi: 10.3390/pharmaceutics15051382

Figure Lengend Snippet: Quantitative analysis of relative protein expression of ZO1 in each BBB model. Endothelial cells (E), Pericytes (P), Astrocytes (A), Fibronectin + Gelatin (F + G), Fibronectin + Collagen (F + C), No substrata (NS) and Magnesium (Mg 2+ ). n = 3, *** = p < 0.001; statistical analysis was performed using one-way ANOVA Bonferroni post hoc tests.

Article Snippet: Immortalised human brain microvascular endothelial cells (I-HBMEC) (Innoprot, Bizkaia, Spain) (P10361-1M), Immortalised human astrocytes (IA) (Innoprot, Bizkaia, Spain) (P10251-1M), CLTH/Immortalised Pericytes (IP) (Amsbio, Oxfordshire, U.K.) (CL05008-CLTH), D-MEM/F:12 (1:1) (CE) (Thermofisher, Cambridge, U.K.) (11320074), Insulin-trans-sel-G, 100× (Thermofisher, Cambridge, U.K.) (41400045), Penicillin streptomycin (PS) (Gibco, Paisley, U.K.) (15070-063), Fetal bovine serum (FBS) (Gibco, Paisley, U.K.) (A3160801), Hydrocortisone solution (50 um) (Merck, Dorset, U.K.) (H6909), Fibroblast growth factor-basic (BFGF) (Merck, Dorset, U.K.) (SRP3043), Heparin sodium salt (Merck, Dorset, U.K.) (H3149), Dulbecco’s phosphate buffered saline, M (DPBS) (Merck, Dorset, U.K.) (D8537), Accutase ® solution (Merck, Dorset, U.K.) (A6964), Tissue culture flask, 75 cm 2 growth area (T75) (Sarstedt, Leicestershire, U.K.) (83.3911.002).

Techniques: Expressing

Journal: Cardiovascular Diabetology

Article Title: Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling

doi: 10.1186/s12933-025-02623-w

Figure Lengend Snippet: Db/db mice + 1% salt show microvascular dysfunction before the onset of diastolic dysfunction. ( A , B ) Cardiac capillary density measured as the number of IB4 + microvessels per area in db/+ and db/db + 1% salt mice at 2, 4, 6 and 8 weeks with representative images ( n = 5–8/group). ( C ) Number of pericytes was determined by counting the cells that were double positive for NG2 and PDGFRb marker, and co-localised with IB4 + microvessels. ( D ) Pericyte coverage, assessed by the ratio of IB4 + microvessels covered by NG2/PDGFRb double positive cells over total IB4 + microvessels. ( E , F ) Active vessel regression, assessed by the ratio of Coll IV + IB4- microvessels over total IB4 + microvessels with representative images at 4 and 6 weeks ( n = 5–8/group). White arrowheads indicate empty collagen sleeves. Scalebars are 6 μm. Values are presented as mean ± SEM. Two-way ANOVA followed by Sidak’s multiple comparisons test with * p < 0.05, ** p < 0.01, and *** p < 0.001. IB4, isolectin B4; NG2, neural glial antigen 2; NS, non-significant; PDGFRb, platelet derived growth factor receptor beta; Coll IV, collagen IV. At 2 weeks: n = 8 F (1 db/+, 7 db/db) and 5 M (4db/+, 1 db/db); at 4 weeks: n = 7 F (4 db/+, 3 db/db) and 8 M (4 db/+, 4db/db); at 6 weeks: n = 7 F (3 db/+, 4 db/db) and 6 M (3 db/+, 3 db/db), at 8 weeks: 4 F (2 db/+, 2db/db) and 6 M (3 db/+, 3 db/db)

Article Snippet: Immortalized human pericytes from 2 male donors (Celther, CL 05008-CLTH) were cultured in DMEM (Thermofisher, 41965039) supplemented with penicillin/streptomycin and 10% fetal bovine serum.

Techniques: Marker, Derivative Assay

Journal: Cardiovascular Diabetology

Article Title: Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling

doi: 10.1186/s12933-025-02623-w

Figure Lengend Snippet: Hearts of db/db mice show arteriole thickening and vessel enlargement after 4 weeks of salt treatment. ( A ) Feature plots for Pdgfrb , Kcnj8 (pericyte marker), Acta2 and Myh11 (VSMC markers) on single cell data of hearts of PDGFRβ-Cre ERT2 -EYFP-db/db + salt and PDGFRβ-Cre ERT2 -EYFP-db/+ mice. ( B ) Violin plot of Acta2 and Myh11 expression in the mural cell population of db/db + salt vs. db/+ mice. ( C ) GO term analysis on the top 500 DEG of the mural cells (FC = 0.25). ( D ) Percentage of ACTA2 positive area in the hearts of db/+ and db/db + 4-week salt mice. Percentage of ACTA2 positive area in ( E ) microvessels (< 10 μm) and ( F ) cardiac pericytes (identified as double positive for NG2 and PDGFRβ) of db/+ and db/db + 4-week salt mice. ( G ) ACTA2 + vessel density measured as the number of ACTA2 + blood vessels per total heart area. ( H ) Distribution of ACTA2 + blood vessels according to vessel size (µm). ( I ) Representative images of ACTA2 + blood vessels in the hearts of db/+ and db/db + 4-week salt mice. Scale bars: 500 μm. ( J ) Measurement of medial area and medial thickness to assess arteriole thickening. All data were analysed by a Student’s t-test with * p < 0.05 and ** p < 0.01 except for data presented in ( H ) which were analysed by Z-statistics to determine a significant difference in distributions. ACTA2, alpha smooth muscle cell actin; NS, non-significant. n = 7 F (4 db/+, 3 db/db) and 8 M (4 db/+, 4db/db)

Article Snippet: Immortalized human pericytes from 2 male donors (Celther, CL 05008-CLTH) were cultured in DMEM (Thermofisher, 41965039) supplemented with penicillin/streptomycin and 10% fetal bovine serum.

Techniques: Marker, Expressing

Journal: Cardiovascular Diabetology

Article Title: Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling

doi: 10.1186/s12933-025-02623-w

Figure Lengend Snippet: Hearts of db/db mice show capillary dilatation and increased pericyte-EC intercellular space after 4 weeks of salt treatment. ( A ) Analysis of the capillary luminal diameter in db/db + 4 weeks 1% salt vs. db/+ mice with representative images ( B ). Scale bar: 10 μm. ( C ) Assessment of proliferation of cardiac pericytes (identified by PDGFRβ) by a Ki67 staining ( n = 7–8/group). White arrowheads indicate proliferating pericytes ( D ). Scale bar: 25 μm. ( E , F ) TEM analysis ( n = 3/group) to determine the intercellular area (E) between EC and pericytes with representative images ( F ). The red dotted line circles the intercellular area. Scale bar: 1 μm

Article Snippet: Immortalized human pericytes from 2 male donors (Celther, CL 05008-CLTH) were cultured in DMEM (Thermofisher, 41965039) supplemented with penicillin/streptomycin and 10% fetal bovine serum.

Techniques: Staining

Journal: Cardiovascular Diabetology

Article Title: Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling

doi: 10.1186/s12933-025-02623-w

Figure Lengend Snippet: Pericyte dysfunction promotes EC inflammation and an EC proliferation arrest through TNFα-dependent paracrine signalling. Predictions of putative ligand-receptor interactions based on NicheNet analysis on the single cell RNA sequencing data between ( A ) the EC (sending) and VSMC_PC (receiver) population and ( B ) the VSMC_PC (sending) population and EC (receiver) population. Human pericytes were exposed to oxidative stress (OX, 100 µM H 2 O 2 ) for 24 h or left untreated (ctrl) and then cocultured for 7 days with ECs. qPCR for ( C ) VCAM1 , IL1A , IL8 and IL6 and ( D ) p21 on EC cocultured with healthy or OX-treated pericytes for 7 days. ( E ) Analysis of proliferation by EDU staining. ( F ) Western blot for cyclin D1, P-STAT1 and total STAT1 on EC cocultured with healthy or OX-treated pericytes for 7 days, with quantification. GAPDH was used as loading control. ( G ) qPCR for TNFA on pericytes exposed to oxidative stress (OX) for 24 h or left untreated (ctrl). ( H , I ) Silencing of TNFA in pericytes, followed by OX treatment (or left untreated), and cocultured with ECs for 7 days. qPCR for VCAM1 ( H ) and analysis of proliferation ( I ) on ECs 7 day cocultured with healthy or OX-treated siTNFA or siCtrl pericytes. All data were analysed by a Student’s t-test or One-way ANOVA with * p < 0.05, ** p < 0.01, *** p < 0.001. IB4, isolectin B4; NS, non-significant; STAT1, signal transducer and activator of transcription 1, TNFA, tumor necrosis factor alpha; VCAM1, vascular adhesion molecule 1. ( J , K ) VCAM1 + microvessels (%) in db/+ and db/db + 1% salt mice with representative images at 4 weeks ( n = 7–8/group). White arrowheads indicate VCAM1 + microvessels (scale bar: 6 μm). ( L , M ) p21 + microvessels in db/+ and db/db + 1% salt mice with representative images at 4 weeks ( n = 6–7/group). White arrowheads indicate endothelial cells positive for p21 (scale bar: 5 μm)

Article Snippet: Immortalized human pericytes from 2 male donors (Celther, CL 05008-CLTH) were cultured in DMEM (Thermofisher, 41965039) supplemented with penicillin/streptomycin and 10% fetal bovine serum.

Techniques: RNA Sequencing, Staining, Western Blot, Control

Journal: Advanced healthcare materials

Article Title: Precision Culture Scaling to Establish High-Throughput Vasculogenesis Models.

doi: 10.1002/adhm.202400388

Figure Lengend Snippet: Figure 5. Effects of vasculogenesis inhibitors on interactions between HRMVECs and HRMVPs. a) 3D image analysis routine to quantify cell-cell contacts (Imaris, Oxford Instruments). 1) The relevant channels are filtered (Gaussian), 2) a channel-specific surface algorithm is performed, 3) the Imaris Xtension ‘surface surface contact area’ is applied for creating a surface at the junction of both cell types. 4) Close-up of contacts (yellow) between HRMVECs (CellTracker Orange, green) and HRMVPs (GFP, orange) (scale bar 1–3. 200 μm and 4. 50 μm). Total filament lengths for b) HRMVECs and c) cocultured HRMVPs. d) Percentage of all HRMVECs surfaces in contact with HRMVPs. e) Total number of contacts. f) Total surface area of contacts. Data presented as violin plots with horizontal lines indicating quartiles 1–3 (n = 4–6). Asterisks indicate multiplicity adjusted P values of one-way ANOVA with post hoc Tukey test, comparing inhibitor treatments to respective vehicle controls; *P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

Article Snippet: Human telomerase reverse transcriptase (hTert) immortalized human retinal microvascular cells (HRMVECs) and hTert immortalized GFPexpressing human retinal microvascular pericytes (HRMVPs), as well as non-fluorescent hTert immortalized HRMVPs (Angio-Proteomie, US), were cultured on tissue culture flasks pre-coated with quick coating solution (Angio-Proteomie, US) in endothelial growth medium and pericyte growth medium (Angio-Proteomie, US) at 37 °C and 5% CO2 in a humidified incubator, respectively.

Techniques:

Journal: Scientific Reports

Article Title: A high-throughput microfluidic bilayer co-culture platform to study endothelial-pericyte interactions

doi: 10.1038/s41598-021-90833-z

Figure Lengend Snippet: Development of the microfluidic microvascular co-culture model in the PREDICT96 platform. ( A ) Side-view schematic of the microvasculature. Capillaries are surrounded by pericytes which, under healthy conditions, help stabilize and mature the endothelium. ( B ) Cross-section schematic showing interaction of endothelial cells (ECs) and pericytes (PCs) through basement membrane. ( C ) Side-view cross-section schematic of the vascular model in the bilayer microfluidic device. ECs and PCs are cultured on either side of a microporous membrane coated with extracellular matrix, which allows interaction between the two cell types. ( D ) Top-view of the PREDICT96 plate, containing an array of 96 bilayer microfluidic devices that interfaces with a 384 well plate top. ( E ) Schematic of PREDICT96 custom pneumatic pump lid, containing 192 individual pumps that control fluid flow in each channel of the 96 bilayer devices. ( F ) A single PREDICT96 device corresponds to 4 wells of the 384 well plate with architecture allowing for culture and fluid flow in separate top and bottom channels, which overlap in the device center. ( G ) Top-view bright field image of a single device, with channel overlap area indicated as the region of interest (dotted rectangle). ( H ) Representative image of ECs stained for PECAM-1 (green) and Hoechst (blue) in channel overlap area.

Article Snippet: Immortalized human retinal pericytes (PCs) were generated by Pfizer and expanded in Angio-Proteomie’s Pericyte Growth Medium (PGM).

Techniques: Co-Culture Assay, Membrane, Cell Culture, Control, Staining